Browse the latest stories and reports on MSF from various media outlets.

Country/Region

September 10, 2013

Jane Coyne speaks about her experience with MSF, MSF's withdrawal from Somalia and the strategies that MSF uses to work in conflict zones.

August 29, 2013

Sophie Delaunay speaks with Leonard Lopate about MSF's difficult decision to leave Somalia and MSF's ongoing response to the catastrophic conflict in Syria.

August 16, 2013

Dr. Unni Karunakara, MSF international president, criticizes Somalia's armed groups and civilian leaders for condoning attacks on MSF's staff, which have forced MSF to withdraw from the country.

August 15, 2013

MSF's Sophie Delaunay describes how the lack of security assurances in Somalia caused MSF to close its programs in the country.

August 15, 2013

MSF international president Dr. Unni Karunakara explains why MSF is closing its programs in Somalia after 22 years of providing lifesaving medical and humanitarian aid in the country.

August 14, 2013

The closure of MSF's programs in Somalia follows years of attacks on its staff. This difficult decision will leave many Somalis without medical and humanitarian aid.

August 14, 2013

MSF is closing all its medical programs in Somalia due to the repeated killing and abduction of its staff by armed groups with the support or acquiescence of civil authorities.

June 28, 2013

A House subcommittee held a hearing on international trade disputes with India. Most of the event was devoted to U.S. drug company Pfizer's complaints about Indian policies that have fostered the country's billion-dollar generics industry.

April 02, 2013

  A landmark ruling by India's Supreme Court underscores the need for patients to have access to generic medications at affordable prices, according to MSF's Jennifer Cohn.

August 21, 2012

Novartis AG goes to India's Supreme Court on Wednesday to seek patent protection for its blockbuster cancer drug Glivec in a case that could deliver far-reaching ramifications for multinational pharmaceutical companies operating in India.... Novartis's critics, including Médecins Sans Frontières [Doctors Without Borders], say that if the company prevails, it could set a legal precedent that allows pharmaceutical giants to patent a range of drugs in India that are now available from generic producers, including HIV medicines. That would demolish a thriving low-cost industry and lead to higher prices, not just in India, they say, but elsewhere in the developing world where India is a major exporter of drugs.

Pages